The goals of the project are to identify and optimize A2A antagonist compounds as therapeutic candidates for Parkinson’s disease and to evaluate these novel compounds in the laboratory.
“We anticipate that this grant will allow us to identify one or more clinical candidates for the treatment of Parkinson’s disease. Our goal is to bring one of these new compounds into clinical trials,” said Robert Capon, CEO and co-founder of Adenosine Therapeutics. “Long term, we are hopeful that this work will lead to more effective treatment for Parkinson’s disease.”
Adenosine Therapeutics was co-founded in 1999 by University of Virginia professor Joel Linden and Virologic co-founder Robert Capon. The company’s most advanced drug development program, a novel pharmacologic stress agent, is in phase II clinical development.